Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management.
Where this comes from
- Record sourced from PubMed, PMID 38319265.
- Also identified by DOI 10.1056/EVIDx2200150.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the Original Article, "Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management," originally published February 3, 2022 (DOI: 10.1056/EVIDoa2100028), in Table 2, the column "Risk Difference or Risk Ratio (95% CI)†," on the twenty-first row, "≥1 gout flares in phase 3," where the text reads "13.4 (-∞ to -3.9)**" should have read "-13.4 (-∞ to -3.9)**". A corrected version of the article has been posted at evidence.nejm.org.